A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands (REWARD)

Amgen

Status: Completed

Conditions: Arthritis, Psoriatic

Study type: Observational

Funder types: Industry

Identifiers

NCT02875184

CC-10004-PSA-009-20200071 (Other Identifier)

CC-10004-PSA-009

Details and patient eligibility

About

This is a multicenter, prospective, non-interventional, observational single arm study.

100 patients will be recruited in the Netherlands over a one year period. In all cases, the decision to treat the patient with apremilast will be made prior to the decision to enter the subject into this study. Treatment will be according to routine clinical practice and based on recommendations as per the Summary of Product Characteristics (SPC) of apremilast (Otezla®). Each patient will be followed up for a maximum of 24 months.

Full description

The objective of this non-interventional study is to describe patient reported outcomes, effectiveness and real-life use of apremilast treatment in patients with psoriatic arthritis (PsA).

Enrollment: 200 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criter

• Patients ≥ 18 years of age who understand and voluntarily sign an informed consent form.
• Patients starting treatment with apremilast for psoriatic arthritis.

Exclusion Criteria:

• Refusal to participate in the study.
• Language barrier for completing the questionnaires.
• Women who are pregnant or breast-feeding.
• Hypersensitivity to the active substance or to any of the excipients.
• Prior exposure to apremilast
• Initiation of apremilast treatment by a dermatologist for psoriasis

Trial design

200 participants in 1 patient group

Psoriatic arthritis patients treated with apremilast

Description:

Psoriatic arthritis patients who are treated with apremilast according to daily practice